- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02410590
Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104) (BENN)
July 10, 2015 updated by: Merck Sharp & Dohme LLC
Randomized, Parallel Group, Controlled Trial to Compare Two Different "NMB + Reversal" Strategies in Adult Obese Patients Undergoing Laparoscopic Abdominal Surgery
The primary objective of this trial is to compare the preference between two strategies of neuromuscular blocking (NMB) / reversal in adult obese patients undergoing laparoscopic abdominal surgery: Rocuronium + Sugammadex versus Succinylcholine + Cisatracurium + Neostigmine/Atropine.
This will be done evaluating the average verbal numerical scale (VNS) scores obtained from surgeons blinded to the drugs administered.
The primary hypothesis is that the strategy "Rocuronium + Sugammadex" provides a better surgical visual field in obese participants undergoing laparoscopic abdominal surgery than the strategy "Succinylcholine + Cisatracurium + Neostigmine/Atropine" as measured by VNS scores.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- must be obese, with a Body Mass Index ≥30.0 to ≤50.
- must be scheduled to undergo an elective abdominal laparoscopic surgery, under general anesthesia. (Participants are expected to remain in the hospital for at least 24 hours following surgical procedure.)
- must be categorized as American Society of Anesthesiologists (ASA) Class 1, 2, or 3.
- clinical laboratory tests within normal limits or clinically acceptable to the investigator/sponsor.
- sexually active females of child-bearing potential must agree to use a medically accepted method of contraception while receiving protocol-specified medication and for the 30 days after stopping the medication. Medically accepted methods of contraception include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed IUD, inert or copper-containing IUD, hormone-releasing IUD, systemic hormonal contraceptive, and surgical sterilization (eg, hysterectomy or tubal ligation). Postmenopausal women are not required to use contraception. Postmenopausal is defined as at least 12 consecutive months without a spontaneous menstrual period. Each sexually active male subject with a female partner(s) of childbearing potential must also provide written informed consent to provide information regarding any pregnancy.
Exclusion Criteria:
- has anatomical malformations that may lead to difficult intubation.
- is known or suspected to have neuromuscular disorders that may affect NMB and/or trial assessments.
- history of previous abdominal laparoscopy procedures.
- must not currently (within past 6 months) meet DSM-IV-TR criteria for substance abuse or dependence (excluding nicotine).
- history of a chronic pain condition (requiring continuous/daily pain medication prior to surgery).
- females who have given birth to one or more children in the last 12 months, or are pregnant or intend to become pregnant between randomization and >Day 30 pregnancy follow-up contact [premenopausal female of childbearing potential].
- evidence of acute cholecystitis.
- dialysis-dependency or suspected of having severe renal insufficiency (defined as estimated creatinine clearance of <30 mL/min).
- significant hepatic dysfunction that would prevent participation in the trial, based on the summary of product characteristics of the study drugs.
- history of or family history of malignant hyperthermia.
- known allergy to trial treatments (rocuronium, sugammadex, succinylcholine, cisatracurium, neostigmine, atropine) or their excipients, to opioids/opiates, or other medication used during general anesthesia.
- expected transfer to intensive care unit after surgery.
- must continue to receive toremifene or fusidic acid during the trial.
- has participated in another clinical trial within 30 days of signing the informed consent form of the current trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rocuronium + Sugammadex
Participants will receive rocuronium administered at a dosage adequate to make intubation possible and provide deep NMB (defined as no response to train-of-four stimulation but at least one response to five post-tetanic count [PTC]) for the duration of surgery, until the end of the procedure.
Sugammadex will be administered to participants once at a dosage of 4 mg/kg real body weight (RBW) IV at the end of surgical procedure.
Sugammadex will be used as the only reversal drug in all participants who receive rocuronium as a neuromuscular blocker.
|
|
Active Comparator: Succinylcholine + Cisatracurium + Neostigmine/Atropine
After receiving succinylcholine 1.0 mg/kg RBW for intubation, participants will receive cisatracurium administered at dosage adequate to have a moderate NMB (defined as a target of TOF ratio = 10% with a range: 2-3 twitches to TOF ratio of 20%) for the duration of surgery, until the end of the procedure.
Neostigmine/Atropine will be administered to participants once at respective dosage of 0.05 mg/kg RBW and 0.01 mg/kg RBW at least after the reappearance of T2 after surgery completion.
The maximum allowed dosage for Neostigmine is 5 mg.
Neostigmine will be used as only reversal drug in all participants who received Cisatracurium as neuromuscular blocker.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Surgeons who prefer Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine for neuromuscular blocking/reversal in obese participants undergoing laparoscopic abdominal surgery
Time Frame: Up to 1 hour after end of surgery
|
Up to 1 hour after end of surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time elapsed from end of surgery to extubation
Time Frame: Up to 1 hour after end of surgery
|
Up to 1 hour after end of surgery
|
Time elapsed from start of reversal drug administration to train-of-four (TOF) ratio ≥0.9
Time Frame: Up to 1 hour after start of reversal drug treatment
|
Up to 1 hour after start of reversal drug treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2015
Primary Completion (Anticipated)
October 1, 2016
Study Completion (Anticipated)
October 1, 2016
Study Registration Dates
First Submitted
April 2, 2015
First Submitted That Met QC Criteria
April 2, 2015
First Posted (Estimate)
April 7, 2015
Study Record Updates
Last Update Posted (Estimate)
July 13, 2015
Last Update Submitted That Met QC Criteria
July 10, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Enzyme Inhibitors
- Adjuvants, Anesthesia
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Neuromuscular Agents
- Cholinesterase Inhibitors
- Mydriatics
- Neuromuscular Nondepolarizing Agents
- Neuromuscular Blocking Agents
- Parasympathomimetics
- Neuromuscular Depolarizing Agents
- Rocuronium
- Atropine
- Cisatracurium
- Neostigmine
- Succinylcholine
Other Study ID Numbers
- 8616-104
- 2013-004423-36 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromuscular Blockade
-
Hospital Federal de BonsucessoUnknownNeuromuscular Blockade | Magnesium Sulfate | Rocuronium | Deep Neuromuscular BlockadeBrazil
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedNeuromuscular Blockade | Neuromuscular MonitoringItaly
-
Universitair Ziekenhuis BrusselUnknownNeuromuscular Blockade | Neuromuscular MonitoringBelgium
-
Central Hospital, Nancy, FranceNot yet recruitingComparison of the TOFscan and the TetraGraph During Recovery of Neuromuscular Function (DECURAR-EMG)Neuromuscular BlockadeFrance
-
Vanderbilt University Medical CenterUniversity of Pittsburgh; The Cooper Health SystemRecruitingNeuromuscular BlockadeUnited States
-
Leiden University Medical CenterMerck Sharp & Dohme LLCCompletedNeuromuscular BlockadeNetherlands
-
Seoul National University Bundang HospitalCompleted
-
Poitiers University HospitalEnrolling by invitationNeuromuscular BlockadeFrance
-
Centre Hospitalier Universitaire Dinant Godinne...CompletedNeuromuscular BlockadeBelgium
-
Seoul National University HospitalCompletedNeuromuscular BlockadeKorea, Republic of
Clinical Trials on Rocuronium
-
Radboud University Medical CenterMerck Sharp & Dohme LLCUnknown
-
Medtronic - MITGCompletedAnesthesia | Neuromuscular BlockadeUnited States
-
University of RostockCompletedObservation of Neuromuscular Block | Complication of Ventilation TherapyGermany
-
Sheba Medical CenterUnknown
-
Pontificia Universidad Catolica de ChileCompletedNeuromuscular Blockade
-
Rigshospitalet, DenmarkCompletedA Comparison of Rocuronium 0.3 mg/kg, and 0.9 mg/kg for Induction of Anesthesia in Elderly Patients.Anesthesia | Intubation Complication | Neuromuscular Blockade | Neuromuscular Blockade, ResidualDenmark
-
SMG-SNU Boramae Medical CenterUnknownSore ThroatKorea, Republic of
-
Merck Sharp & Dohme LLCCompleted
-
Memorial Sloan Kettering Cancer CenterRecruitingProstate CancerUnited States
-
Asan Medical CenterCompletedNeuromuscular BlockadeKorea, Republic of